Pfizer Inc Board Elects Henry McKinnell President and Chief Operating Officer; John Niblack Elected Vice Chairman
NEW YORK, May 27 /PRNewswire/ -- William C. Steere, Jr., chairman of the board and chief executive officer of Pfizer Inc (NYSE: PFE), announced today that Henry A. McKinnell, Ph.D., executive vice president and president, Pfizer Pharmaceuticals Group, has been elected president and chief operating officer of Pfizer Inc. Mr. Steere also announced the election of John F. Niblack, Ph.D., executive vice president, as vice chairman, Pfizer Inc. The election took place at the Board's meeting today as a step in the process to ensure a smooth transition in the leadership of the company, looking forward toward June 2001, Mr. Steere's normal retirement date.
In addition, C.L. Clemente, senior vice president, Corporate Affairs; Paul S. Miller, senior vice president and general counsel; William J. Robison, senior vice president, Corporate Employee Resources; and David L. Shedlarz, senior vice president and chief financial officer, were elected executive vice presidents of Pfizer Inc.
Karen L. Katen, vice president of Pfizer Inc, executive vice president, Pfizer Pharmaceuticals Group, and president, U.S. Pharmaceuticals; and George M. Milne, Jr., Ph.D., vice president of Pfizer Inc and president, Central Research, were elected senior vice presidents of the Company.
Dr. McKinnell began his Pfizer career in 1971 in Tokyo, Japan. Over the years, he held positions of increasing responsibility for Pfizer operations around the world, serving as president of Pfizer Asia, based in Hong Kong. He also served as Pfizer's chief financial officer and was president of the Medical Technology Group. In 1997, he assumed responsibility for Pfizer's principal operating group, Pfizer Pharmaceuticals, and was also responsible for the worldwide Consumer Health Care business and Corporate Strategic Planning and Policy.
Dr. McKinnell earned a Bachelor's degree in business from the University of British Columbia and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business.
Dr. Niblack joined Pfizer in 1967 as a molecular biologist at Groton, where he held positions of increasing responsibility. In 1980, Dr. Niblack was named director of Research for Pfizer's U.S. drug discovery operations. In 1986, he was promoted to executive vice president of the Central Research Division, responsible for worldwide drug development activities. He was appointed president of the Central Research Division in 1990, and in 1993, he became executive vice president, Research and Development, Pfizer Inc. In 1997, he was named executive vice president, Pfizer Inc, responsible for the Central Research, Animal Health, Licensing and Development, and Quality Control divisions.
Dr. Niblack earned a B.S. degree in chemistry from Oklahoma State University and M.S. and Ph.D. degrees in biochemistry from the University of Illinois.
Pfizer Inc is a research-based global pharmaceutical company that discovers, develops, manufactures and markets innovative medicines for humans and animals. The company reported revenues of more than $13.5 billion in 1998 and spent more than $2.2 billion on research and development. In 1999, Pfizer celebrates its 150th anniversary.
SOURCE Pfizer Inc
CO: Pfizer Inc
ST: New York
IN: MTC
SU: PER
05/27/99 10:50 EDT prnewswire.com
|
